Physician profile
Anna Kravtsov
NPI 1114243805
$2,887.27
in general payments reported to CMS, 2019-2025
17 companies · $537 in 2025
The $537 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $954 · 2020: $142 · 2021: $305 · 2022: $130 · 2023: $111 · 2024: $708 · 2025: $537.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,356.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,355.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $824.85 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $594.11 | 2019-2025 | Rexulti, Abilify Maintena |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $300.15 | 2023-2025 | Caplyta |
| Allergan, INC. | $270.52 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $145.63 | 2019-2025 | Uzedy |
| Sunovion Pharmaceuticals INC. | $125.79 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $103.37 | 2019-2025 | Trintellix |
| Vanda Pharmaceuticals INC. | $92.30 | 2019-2025 | Fanapt |
| Bausch Health US, LLC | $89.13 | 2019-2024 | Aplenzin |
| Neurocrine Biosciences, INC. | $81.71 | 2019-2025 | |
| Lundbeck LLC | $79.27 | 2019-2025 | Rexulti |
| Alkermes, INC. | $67.47 | 2025 | Aristada, Lybalvi |
| Avanir Pharmaceuticals, INC. | $44.63 | 2019-2020 | |
| Validus Pharmaceuticals LLC | $26.58 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $14.38 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $13.73 | 2019 | |
| Axsome Therapeutics, INC. | $13.65 | 2025 | Auvelity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Kravtsov listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.